This HCP Educational Information Brochure aims to provide information about Differentiation Syndrome related to Gilteritinib Astellas, to minimise the risk associated with this safety concern. The brochure contains the following: -Information on Gilteritinib Astellas, including the approved indication according to the SmPC. -Description of the signs and symptoms of differentiation syndrome. -Management of differentiation syndrome

Every Gilteritinib Astellas 40 mg film-coated tablets pack contains a patient alert card. The purpose of the patient alert card is to provide: -Information for patients that Gilteritinib Astellas treatment may cause differentiation syndrome. -Description of signs or symptoms of the safety concern and when to seek medical care if differentiation syndrome is suspected -A warning message for healthcare professionals treating the patient at any time, including in conditions of emergency, that the patient is using Gilteritinib Astellas. -Contact details of the treating physician who has prescribed Gilteritinib Astellas. -Needs to be carried all the time and presented to any healthcare professional.